Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers
NCT ID: NCT04231136
Last Updated: 2020-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
19 participants
INTERVENTIONAL
2020-01-14
2020-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Pharmacodynamic assessments with intragastric pH
* Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tegoprazan 50 mg
Oral administration of Tegoprazan 50 mg tablet once a day
Tegoprazan 50 mg
Tegoprazan 50 mg tablet
EAPA115
Oral administration of EAPA115 once a day
EAPA115
EAPA115
RAPA115
Oral administration of RAPA115 once a day
RAPA115
RAPA115
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tegoprazan 50 mg
Tegoprazan 50 mg tablet
EAPA115
EAPA115
RAPA115
RAPA115
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) ≥ 17.5 and \< 30.5 kg/m\^2 with a body weight ≥ 45 kg at screening. Body mass index (kg/m\^2) = weight (kg)/height (m)\^2
* Confirmed as H. pylori negative
* A subject without any congenital or chronic disease within 3 years, and has no medical examination result as pathological symptoms or signs.
* A subject determined eligible for this study based on the screening test such as clinical laboratory tests (hematology test, chemistry test, urine test, virus/bacteria test, etc.), vital signs, and electrocardiogram.
* A subject who is fully informed of the purpose and content of the study and agrees to participate in the study on its own will and signs the consent form approved by the Institutional Review Board (IRB) of the Seoul National University Hospital, prior to participate in the study.
* A subject who has the ability and willingness to participate throughout the whole study period.
Exclusion Criteria
* A subject with a history of gastrointestinal disorders (esophageal diseases such as esophageal achalasia or esophageal stricture, Crohn's disease) or surgery (except for simple appendectomy, herniotomy, and tooth extraction surgery) that may affect the absorption of drugs.
* A subject with the \*17 allele of CYP2C19 (Ultrarapid metabolizer).
* A subject with AST and ALT levels exceeding 3 times of the upper limit of the reference range in the screening test.
* A subject with a history of excessive caffeine (\> 5 units/day) or regular alcohol consumption exceeding 210 g/week within 6 months of screening test. (1 glass of beer (5%) (250 mL) = 10 g, 1 shot of soju (20%) (50 mL) = 8 g, 1 glass of wine (12%) (125 mL) = 12 g)
* A subject who participated in other clinical trial or bioequivalence study and administered the study medication within 6 months prior to the first administration of the investigational product of this study.
* A subject with significant alcohol or drug abuse within a year of screening test.
* A subject who administered drugs that significantly induce or inhibit drug metabolizing enzymes within 30 days prior to the first administration of the investigational product of this study.
* A subject who smoked cigarettes more than 20 per day within 6 months of screening test.
* A subject who administered prescribed drug or over-the-counter drug within 10 days prior to the first administration of the investigational product of this study.
* A subject who has donated whole blood within 2 months or those who donated the component blood within 1 month prior to the first administration of the investigational product of this study.
* A subject who has hypersensitivity to the investigational product of this study, benzimidazoles, penicillin and macrolide and its related medical history.
* A subject with rare genetic problems such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency.
* Pregnant or nursing women
* A subject who cannot use reliable contraception during the entire period of the clinical trial (e.g, condom use, intrauterine device, tubal ligation, cervical cap, contraceptive diaphragm, etc.).
* A subject who is judged by the investigator to be ineligible to participate in the test.
19 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HK inno.N Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
In-Jin Jang, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital, Dept. of Clinical Pharmacology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital, Clinical Trial Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CJ_APA_115
Identifier Type: -
Identifier Source: org_study_id